Prospects for AbbVie Inc.’s Venclexta (venetoclax) becoming a fully approved treatment for acute myeloid leukemia (AML) were thrown into doubt when the B-cell lymphoma-2 inhibitor failed to show a significant improvement in the primary endpoint of overall survival (OS) in the ongoing VIALE-C Phase III study, although it did demonstrate numerical improvement.
AbbVie’s Venclexta Fails In Combo AML Trial
Pfizer’s Daurismo May Benefit From Venclexta’s VIALE-C Setback
AbbVie’s Venclexta failed to show a significant improvement in the primary endpoint of overall survival in the Phase III VIALE-C for AML, but there was numerical improvement. Its setback is good news for Pfizer’s rival Daurismo, analysts said.
